Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Case Report: Uromodulin-associated autosomal dominant tubulointerstitial kidney disease: case analysis and literature review.

Created on 13 Nov 2026

Authors

Linlin Zheng, Hui Gao, Xiangkai Zheng, Xing Zhang, Xiaona Wei

Published in

Frontiers in nephrology. Volume 6. Pages 1931661. Epub Oct 29, 2026.

Abstract

Autosomal dominant tubulointerstitial kidney disease caused by UMOD variants (ADTKD-UMOD) is a rare hereditary disorder characterized by early-onset hyperuricemia, gout, and progressive kidney dysfunction. Diagnosis is established by genetic testing. We report the case of a 25-year-old man who presented with elevated serum creatinine (Scr) and uric acid (UA) levels. His father and elder sister had chronic kidney disease of unknown etiology, suggesting an autosomal dominant inheritance pattern. A comprehensive evaluation excluded secondary causes of hyperuricemia and kidney dysfunction. Genetic testing identified a novel heterozygous missense variant, UMOD (NM_003361.4): c.274T>A (p.Cys92Ser), in exon 3 of the gene. The same variant was also detected in affected relatives. In silico analyses predicted a deleterious effect, and the variant was classified as likely pathogenic according to the ACMG/AMP criteria (PM5_Moderate, PP3_Moderate, PM2_Supporting). During longitudinal follow-up with febuxostat treatment, serum urate levels decreased, while progressive deterioration of renal function was observed during the observational period. By analogy to well-characterized pathogenic cysteine-altering UMOD variants, we hypothesize that p.Cys92Ser may promote uromodulin misfolding and endoplasmic reticulum retention and thereby contribute to kidney injury; this mechanistic inference remains to be verified by direct functional experiments for this novel variant. This report expands the mutational spectrum of ADTKD-UMOD and underscores the importance of early genetic testing in at-risk families, as well as standardized long-term follow-up and management for this progressive disorder.

PMID:
43021960
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement